Fisher Asset Management LLC Decreases Holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Fisher Asset Management LLC reduced its stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 88.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 47,198 shares of the life sciences company’s stock after selling 352,525 shares during the period. Fisher Asset Management LLC owned 0.06% of Integra LifeSciences worth $1,070,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of the stock. KBC Group NV raised its position in shares of Integra LifeSciences by 65.2% during the 3rd quarter. KBC Group NV now owns 2,839 shares of the life sciences company’s stock worth $52,000 after purchasing an additional 1,120 shares during the last quarter. New York State Teachers Retirement System raised its position in shares of Integra LifeSciences by 3.0% during the 3rd quarter. New York State Teachers Retirement System now owns 90,098 shares of the life sciences company’s stock worth $1,637,000 after purchasing an additional 2,616 shares during the last quarter. Nisa Investment Advisors LLC raised its holdings in Integra LifeSciences by 599.6% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company’s stock valued at $74,000 after acquiring an additional 2,800 shares during the last quarter. Nordea Investment Management AB raised its holdings in Integra LifeSciences by 4.1% in the 4th quarter. Nordea Investment Management AB now owns 127,908 shares of the life sciences company’s stock valued at $2,919,000 after acquiring an additional 5,032 shares during the last quarter. Finally, Choreo LLC raised its holdings in Integra LifeSciences by 29.9% in the 4th quarter. Choreo LLC now owns 22,274 shares of the life sciences company’s stock valued at $500,000 after acquiring an additional 5,123 shares during the last quarter. 84.78% of the stock is currently owned by institutional investors and hedge funds.

Integra LifeSciences Stock Down 0.2 %

Shares of Integra LifeSciences stock opened at $21.87 on Thursday. The company has a fifty day moving average price of $23.79 and a 200 day moving average price of $21.88. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79. Integra LifeSciences Holdings Co. has a twelve month low of $16.81 and a twelve month high of $36.99. The stock has a market cap of $1.69 billion, a price-to-earnings ratio of -242.97, a price-to-earnings-growth ratio of 0.73 and a beta of 1.17.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings results on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share for the quarter, topping analysts’ consensus estimates of $0.85 by $0.12. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The firm had revenue of $442.65 million during the quarter, compared to analysts’ expectations of $445.15 million. During the same period in the prior year, the company earned $0.89 EPS. The firm’s revenue was up 11.5% on a year-over-year basis. Equities research analysts forecast that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley assumed coverage on Integra LifeSciences in a report on Monday, December 2nd. They issued an “underweight” rating and a $20.00 price target for the company. Three analysts have rated the stock with a sell rating, five have issued a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $23.00.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.